Oral Oncology
Volume 40, Issue 5 , Pages 525-531 , May 2004

Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma

  • Vincenzo Adamo

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-90-221-3238; fax: +39-90-221-3231
    • ,
  • Giuseppa Ferraro

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • ,
  • Stefano Pergolizzi

      Affiliations

    • Department of Radiological Science, Azienda Ospedaliera Universitaria, Policlinico “G. Martino”, 98125 Messina, Italy
    • ,
  • Concetta Sergi

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • ,
  • Agata Laudani

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • ,
  • Nicola Settineri

      Affiliations

    • Department of Radiological Science, Azienda Ospedaliera Universitaria, Policlinico “G. Martino”, 98125 Messina, Italy
    • ,
  • Elisabetta Alafaci

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • ,
  • Antonino Scimone

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy
    • ,
  • Franca Spano

      Affiliations

    • Department of Surgery, Unit of Ear–Nose–Throat, Azienda Ospedaliera Universitaria, Policlinico “G. Martino”, 98125 Messina, Italy
    • ,
  • Gianluca Spitaleri

      Affiliations

    • Department of Human Pathology, Unit of Clinical Oncology, Azienda Ospedaliera Universitaria, Policlinico “G. Martino” via C. Valeria No. 1, 98125 Messina, Italy

Received 1 October 2003 ,Accepted 29 October 2003.

References 

  1. Vokes EE, Weichselbaum RR, Lippmann SM, et al.  Head and neck cancer. N. Engl. J. Med. 1993;328:184–194
  2. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In:  De Vita V,  Hellman S,  Rosenberg S editor. Cancer: principles and practice of oncology. 6th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 797–850
  3. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  4. Liggett W, Forastiere AA. Chemotherapy advances in head and neck oncology. Semin. Surg. Oncol. 1995;11:265–271
  5. Jassem J, Bartelink H. Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. Cancer Treatm. Rev. 1995;21:447–462
  6. Jacobs C, Lyman G, Valez-Garcia E, et al.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992;10:257–263
  7. Forastiere AA, Metch B, Schuller DE, et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of head and neck: a southwest oncology group study. J. Clin. Oncol. 1992;10:1245–1251
  8. Clavel M, Vermoken JB, Cognetti F, et al.  Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin in recurrent or metastatic squamous cell carcinoma of head and neck. A phase III study of EORTC Head and Neck Center Cooperative Group. Ann. Oncol. 1994;5:521–526
  9. Eisenhauuer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5–30
  10. Gan Y, Wientjes MG, Schuller DE, et al.  Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 1996;56:2086–2093
  11. Smith R, Thornton D, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of head and neck with correlative laboratory studies. Semin. Oncol. 1995;22:41–46
  12. Gebbia V, Testa A, Cannata G, et al.  Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur. J. Cancer A. 1996;32:901–902
  13. Forastiere AA, Shank D, Neuberg D, et al.  Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998;82:2270–2274
  14. Vermoken JB, Catimel G, De Mulder P, et al.  Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (taxol) in patients with metastatic of recurrent squamous cell carcinoma of head and neck. Proc. Am. Soc. Clin. Oncol. 1999;18:395a
  15. Rowinsky EK, Gilbert MR, McGuire WP, et al.  Sequences of taxol and cisplatin a phase I and pharmacology study. J. Clin. Oncol. 1991;9:1692–1703
  16. Dunphy F, Boyd J, Dunleavy T. Paclitaxel and carboplatin in head and neck cancer. Semin. Oncol. 1997;24(6 suppl. 19):S19-25–S19-27
  17. Clark JI, Hofmeister G, Choudhury A, et al.  Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer. 2001;92:2334–2340
  18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al.  European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J. Clin. Oncol. 1994;12:2654–2666
  19. Khuri FR, Dong M, Glisson BS, et al.  Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin. Oncol. 2000;27(8):25–33
  20. Schilling T, Heinrich B, Kau R, et al.  Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology. 1997;54(2):89–95
  21. Licitra L, Capri G, Fulfaro F, et al.  Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann. Oncol. 1997;8(11):1157–1158
  22. Thodtmann F, Theiss F, Kemmerich M, et al.  Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol. 1998;9(3):335–337
  23. Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin. Oncol. 1999;26(1 suppl. 2):100–105
  24. Basaran M, Bavbek SE, Gullu T, et al.  A phase II of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J. Chemother. 2002;14(2):207–213
  25. Tummarello D, Berardi R, Battelli N, et al.  Paclitaxel (TX) plus cisplatin (CDDP) or carboplatin (CBCDA) an active combination in recurrent carcinoma of the head and neck (H&N). Proc. Am. Soc. Clin. Oncol. 2002;21:2575a
  26. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. The Oncologist. 2000;5(3):199–208
  27. Glisson BS, Murphy BA, Frenette G, et al.  Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2002;20(6):1593–1599
  28. Forastiere AA, Loang T, Rowinsky E, et al.  Phase III comparison of high-dose paclitaxel+cisplatin+granulocyte colony-stimulating factor versus low-dose paclitaxel+cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E 1393. J. Clin. Oncol. 2001;19(4):1088–1095
  29. Murphy B, Li Y, Cella D, et al.  Phase III study comparing cisplatin (C) & 5Fluorouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). Proc. Am. Soc. Clin. Oncol. 2001;20:894a
  30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481

PII: S1368-8375(03)00234-3

doi: 10.1016/j.oraloncology.2003.10.010

Oral Oncology
Volume 40, Issue 5 , Pages 525-531 , May 2004

Article Tools

* Image Usage & Resolution